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• A high throughput UPC2‐MS/MS method for the analysis of 19 steroids is described 
• UPC2‐MS/MS offers superior selectivity and increased chromatographic efficiency 
• Significant improvements in sensitivity were achieved by UPC2‐MS/MS 
• UPC2‐MS/MS is a SFC based technology which is ideal for steroid analysis 
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Abstract 
11-oxygenated steroids such as 11-ketotestosterone and 11-ketodihydrotestosterone 
have recently been shown to play a putative role in the development and progression 
of castration resistant prostate cancer. In this study we report on the development of 
a high throughput ultra-performance convergence chromatography tandem mass 
spectrometry (UPC2-MS/MS) method for the analysis of thirteen 11-oxygenated and 
six canonical C19 steroids isolated from a cell culture matrix. Using an Acquity UPC2 
BEH 2-EP column we found that UPC2 resulted in superior selectivity, increased 
chromatographic efficiency and a scattered elution order when compared to 
conventional reverse phase ultra-performance liquid chromatography (UPLC). 
Furthermore, there was a significant improvement in sensitivity (5-50 times). The 
lower limits of quantification ranged between 0.01 to 10 ng mL-1, while the upper limit 
of quantification was 100 ng mL-1 for all steroids. Accuracy, precision, intra-day 
variation, recovery, matrix effects and process efficiency were all evaluated and 
found to be within acceptable limits. Taken together we show that the increased 
power of UPC2-MS/MS allows the analyst for the first time to complete in vitro assays 
at biologically relevant concentrations and in so doing determine the routes of steroid 
metabolism which is vital for studies of androgen responsive cancers, such as 
prostate cancer, and could highlight new mechanisms of disease progression and 
new targets for cancer therapy.  
 
Keywords: Adrenal androgens; Gas chromatography; Steroids; Supercritical fluid 
chromatography; Ultra performance convergence chromatography; Ultra 
performance liquid chromatography 
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Abbreviations:   
3α-adiol, 5α-androstane-3α,17β-diol; 5α-dione, 5α-androstanedione; 11K-3α-adiol, 
11keto-5α-androstane-3α,17β-diol; 11K-5α-dione; 11keto-5α-androstanedione; 
11KA4, 11-ketoandrostenedione; 11KAST, 11-ketoandrosterone; 11KDHT, 11-
ketodihydrotestosterone; 11KepiAST, 11-ketoepiandrosterone; 11KT, 11-
ketotestosterone; 11OH-5α-dione, 11β-hydroxy-5α-androstanedione; 11OHA4, 11β-
hydroxyandrostenedione;  11OHAST, 11β-hydroxyandrosterone; 11OHDHT, 11β-
hydroxydihydrotestosterone; 11OHepiAST, 11β-hydroxyepiandrosterone; 11OHT, 
11β-hydroxytestosterone; A4; androstenedione; DHT, 5α-dihydrotestosterone; 
DRSP, drospirenone; epiAST, epiandrosterone; GES, gestodene; T, testosterone  
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1 Introduction 
Steroids hormones play a vital role in the regulation of a number of physiological 
processes, which include the regulation of water and electrolyte balance, 
metabolism, stress response, inflammation and reproductive functions [1]. In 
addition, endocrine disorders such as congenital adrenal hyperplasia (CAH), 
Cushing’s syndrome, polycystic ovary syndrome (PCOS), primary aldosteronism and 
hormone dependent cancers, as well as prostate and breast cancer are associated 
with the dysregulated production of steroid hormones[2–6]. Accurate quantification of 
steroid hormones is therefore essential for both diagnostic and research purposes.  
All steroid hormones are derived from cholesterol and share the basic 
cyclopentanoperhydrophenanthrene ring structure. The physiological function of 
individual steroid hormones is determined primarily by modifications to the basic 4- 
ring steroid structure such as the position of specific double bonds, or the position of 
hydroxyl or keto functional groups [1]. These subtle structural differences, unique to 
each steroid hormone, significantly complicate the separation of such structurally 
similar molecules, which include isobaric species. Although good resolution and 
sensitivity are achieved by gas chromatography-mass spectrometry (GC-MS), this 
requires laborious sample preparation, including hydrolysis and derivatisation, and is 
not applicable to high-throughput assays. While liquid chromatography tandem mass 
spectrometry (LC-MS/MS) does not achieve the resolution offered by GC-MS, in 
most cases LC-MS/MS does not require sample derivatisation and ultra-high 
performance liquid chromatography (UHPLC) instrumentation offer significantly 
reduced runtimes compared to traditional LC [7,8].  
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Enhanced chromatographic efficiency and resolution are achieved by supercritical 
fluid chromatography (SFC) which, due to the unique properties of supercritical fluids 
(SFs), is able to combine the benefits of both GC and LC. SFs have liquid-like 
densities and dissolving capacities, but demonstrate high gas-like diffusivity and low 
viscosities [9–11]. The idea of converging ultra-high pressure gas chromatography 
with classical liquid chromatography was  first proposed by Giddings in 1964 [11]. 
The convergence of a supercritical mobile phase with liquid organic modifiers 
maintains the benefits of SFC, with the additional benefits of increased versatility and 
selectivity [12]. Reproducible analytical output by convergence chromatography is 
dependent on the ability to control key parameters such as temperature, pressure 
and density, which, being technically difficult, was only recently achieved, with 
advances in technology resulting in commercially viable convergence systems [11]. 
The Waters Ultra-Performance Convergence Chromatography™ (UPC2) system 
used in this study makes use of highly miscible supercritical CO2 which can be 
modified by the addition of organic solvents with relative polarities ranging from that 
of for example hexane (0.009) to methanol (0.762) [13]. Furthermore, the 
compatibility of the mobile phase with a wide range of small-particle stationary 
phases offers a vast range of selectivity [11]. UPC2, when coupled to highly sensitive 
tandem mass spectrometry becomes a powerful tool for separating and quantifying 
trace levels of analytes such as complex steroid hormones. Recent advances in 
mass spectrometry such as the inclusion of measures maximising ion transmission 
to the detector while removing neutral interferences, has led to increases in 
sensitivity by increasing the signal to noise (S/N) ratio. Our laboratory has clearly 
demonstrated the resolving power of UPC2 when applied to steroid metabolites [14].  
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The aim of this study was to develop and validate a method, utilizing UPC2-MS/MS, 
for the separation and quantification of the classical androgens and structurally 
related 11-oxygenated C19 steroid hormones.  The latter group of steroid metabolites 
were recently identified in the metabolism of 11β-hydroxyandrostenedione 
(11OHA4), a major C19 adrenal androgen, which has been implicated as a role 
player in castration resistant prostate cancer (CRPC) (Fig.1) [14–17]. Significantly, 
two of the resulting steroids, 11-ketotestosterone (11KT) and 11-
ketodihydrotestosterone (11KDHT) have recently been shown to be potent 
androgens, comparable to testosterone and DHT, respectively [18]. As multiple 
routes from 11OHA4 to 11KDHT exist, it is vital that the individual enzymatic steps 
as well as the pathway as a whole is characterised. To this end the current method 
was developed which allows for in vitro assays to be performed at physiologically 
relevant concentrations. The resulting method not only demonstrates the analytical 
power achieved by the UPC2-MS/MS system, but also provides a necessary tool to 
further elucidate the role of steroid metabolites in the development and progression 
of CRPC and other androgen dependent tumours. 
 
2 Experimental section 
2.1 Reagents  
2.1.1 Steroid standards 
Androstenedione (A4) and testosterone (T) were purchased from Sigma-Aldrich 
(Steinheim, Germany) and Fluka (Neu-Ulm, Germany), respectively. 11β-
hydroxyandrostenedione (11OHA4), 11-ketoandrostenedione (11KA4), 11β-
hydroxytestosterone (11OHT), 11-ketotestosterone (11KT), 5α-androstanedione (5α-
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dione), epiandrosterone (epiAST), 5α-dihydrotestosterone (DHT), 11-
ketodihydrotestosterone (11KDHT), 5α-androstane-3α,17β-diol (3α-adiol), 11β-
hydroxyandrosterone (11OHAST), 11β-hydroxyepiandrosterone (11OHepiAST), 11-
ketoandrosterone (11KAST) and 11-ketoepiandrosterone (11KepiAST) were 
purchased from Steraloids (Wilton, USA). 
2.1.2 Production of steroids which are not available commercially 
The steroids 11β-hydroxy-5α-androstanedione (11OH-5αdione), 11keto-5α-
androstanedione (11K-5αdione), 11β-hydroxydihydrotestosterone (11OHDHT) and 
11keto-5α-androstane-3α, 17β-diol (11K-3α-adiol) were prepared using HEK293 
cells transiently transfected with steroid 5α-reductase type 1 (SRD5A1) or 3α-
hydroxysteroid dehydrogenase type 3 (AKR1C2) as previously described [15]. 
2.2.3 Internal standards 
Gestodene (GES) and drospirenone (DRSP) were purchased from Sigma-Aldrich 
(Steinheim, Germany). Cortisol-9, 11, 12, 12-d4 (cortisol-d4) and testosterone-1, 2-d2 
(T-d2), progesterone-2, 2, 4, 6, 6, 17α, 21, 21, 21-d9 (Prog-d9) and 4-pregnen-17α-ol-
3,20-dione-2, 2, 4, 6, 6, 21, 21, 21-d8 (17OHProg-d8) were purchased from 
Cambridge Isotope Laboratories (Andover, MA, USA). 
2.1.4 Solvents 
FOODFRESH CO2 was purchased from Afrox (Cape Town, South Africa). UHPLC 
grade methanol, formic acid, and tert-Methyl Butyl Ether (MTBE) were purchased 
from Sigma-Aldrich (Steinheim, Germany). 
2.2 Preparation of standards and samples 
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Individual stock solutions of the fifteen commercially available steroids (A4, T, 
11OHA4, 11KA4, 11OHT, 11KT, 5α-dione, epiAST, DHT, 3α-adiol, 11KDHT, 
11OHAST, 11OHepiAST, 11KAST and 11KepiAST) were prepared in absolute 
ethanol (1 mg mL-1) and stored at −20 °C until use. These individual stock solutions 
were later used to prepare two standard master mixes (1000 ng mL-1 and 1 ng mL-1) 
in methanol, which contained all of the above mentioned steroids. These standard 
master mixes were subsequently used to prepare standards (1mL, 0.01– 250 ng mL-
1) by the addition of the appropriate volume of the standard master mix to either 
DMEM containing 1% penicillin-streptomycin and 10% fetal bovine serum (matrix) or 
50% methanol (no matrix). Samples used for method validation (1 mL) were 
prepared by spiking the matrix (DMEM containing 1% penicillin-streptomycin and 
10% fetal bovine serum), with the appropriate volume of the standard master mix.   
2.3 Steroid extractions  
Fifty microliters of an internal standard mixture containing 15 ng cortisol-d4, 1.5 ng T-
d2, 15 ng 17OHP4-d9, 15 ng P4-d9, 12.4 ng GES and 14.7 ng DRSP was added to 
each sample and standard prior to extraction. Samples and standards were 
extracted using a 1:3 ratio of sample to MTBE (vol vol-1). The samples were shaken 
at 1000 RPM for 15 min before being placed at -80°C for an hour to allow the 
aqueous phase to freeze. The MTBE layer containing steroids was transferred to a 
pyrolysed glass test tube and the MTBE evaporated at 55°C under a stream of 
nitrogen gas. Samples were subsequently reconstituted in 150 µL 50% methanol and 
stored at −20°C prior to analysis.  
2.4 Instruments and chromatographic conditions 
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Steroid metabolites were separated using an Acquity UPC2 system (Waters 
Corporation, Milford, USA) with an Acquity UPC2 BEH 2-EP column (3 mm X 100 
mm, 1.7 µm particle size). The mobile phase consisted of liquid CO2 modified with 
methanol. A 4 min linear gradient from 2% to 9.5% methanol was used to separate 
the C19 steroids using a constant flow rate of 2.0 mL min
-1. The column temperature 
and automated back pressure regulator (ABPR) were set to 60°C and 2000 psi, 
respectively. The injection volume was 2.0 µL. Quantitative mass spectrometric 
detection was carried out using a Xevo TQ-S triple quadrupole mass spectrometer 
(Waters, Milford, USA). A make-up pump was attached to this coupler which fed 1% 
formic acid in methanol into the mixer preceding the MS line at a constant flow rate 
of 0.2 mL min-1. All steroids were analysed in multiple reaction monitoring (MRM) 
mode using an electrospray probe in the positive ionization mode (ESI+). The 
following settings were used: capillary voltage of 3.8 kV, source temperature 120°C, 
desolvation temperature 500°C, desolvation gas 1000 L h−1 and cone gas 150 L h−1. 
MRM settings are included in table1. Data collection and analysis were performed 
using MassLynx 4.1 (Waters Corporation).  
2.5 Method validation 
Standard curves were generated for each steroid metabolite using standards 
prepared in matrix or 50% methanol and included the following concentrations: 0, 
0.01, 0.05, 0.1, 0.25, 0.5, 1.0, 5.0, 10, 25, 50, 100 and 250 ng mL-1. The limit of 
detection (LOD) for each steroid metabolite was defined as the lowest concentration 
at which a signal-to-noise (S/N) ratio greater than 3 was measured for the quantifier 
ion. The limit of quantification (LOQ) was defined as the lowest concentration for 
each steroid at which a S/N ratio greater than 10 was measured for quantifier ion, 
and a S/N ratio greater than 3 measured for the qualifier ion, and which could be 
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measured with acceptable precision (≤20%) expressed as percent relative standard 
deviation (%RSD). The upper limit of quantification was defined as the highest 
concentration for each steroid which fit a linear standard curve, and which could be 
measured with acceptable precision (≤15%) expressed as percent relative standard 
deviation (%RSD). Linearity of the standard curves was assessed using the Runs 
test in Graphpad Prism. Accuracy and precision were determined for the following 
concentrations: 0.25, 2.5, 25, 50 and 100 ng mL-1.Accuracy was defined as the 
%RSD from the average calculated concentration following the repeated injection 
(n=8) of a single sample. Precision was defined as the %RSD from the analysis of 
independent replicate samples (n=6) and was repeated over three days in order to 
assess inter day variation. Precision was also used to assess within-laboratory 
reproducibility for two assessors over four days for the concentrations 25 and 100 ng 
mL-1. Recovery, matrix effect and process efficiency were determined at three 
concentrations (2.5, 50 and 100 ng mL-1, n=3) for each steroid using the method 
described by Taylor et al 2005 [19]. Briefly, steroid recovery was calculated by 
comparing the response of standards prepared in media and extracted as described 
above to that of media extracts with the post-extraction addition of steroids. Similarly 
matrix effects were determined by comparing media extracts with the post-extraction 
addition of steroids to a pure solution of 50% methanol containing equivalent 
amounts of steroid. The difference in response between the post-extraction samples 
and the pure standards were divided by the response of the pure standards. The 
overall process efficiency, which is the combination of recovery and matrix effects, 
was calculated by comparing the response of standards prepared in media (pre-
extraction) to that of pure standards.  
2.6 Comparative separation and quantification by UPLC-MS/MS 
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Steroid metabolites were separated using a UPLC hollow structural section (HSS) T3 
column (2.1 mm x 50 mm, 1.8 μm) (Waters, Milford, USA) coupled to an ACQUITY 
UPLC (Waters, Milford, USA) as previously described [4]. The mobile phases 
consisted of (A) 0.1% formic acid and (B) 100% methanol. A 5 min linear gradient 
from 55% A to 75% B was used to separate the C19 steroids using a constant flow 
rate of 0.6 mL min-1 and a column temperature of 50°C. The injection volume was 
20.0 µL. Quantitative mass spectrometric detection was carried out using a Xevo TQ 
triple quadrupole mass spectrometer (Waters, Milford, USA). All steroids were 
analysed in multiple reaction monitoring (MRM) mode using an electrospray probe in 
the positive ionization mode (ESI+). The following settings were used: capillary 
voltage of 4.0 kV, source temperature 150°C, desolvation temperature 500°C, 
desolvation gas 1000 L h−1 and cone gas 150 L h−1. Data collection and analysis 
were performed using MassLynx 4.1 (Waters Corporation).  
 
3 Results 
3.1 Separation by UPC2 
We have developed an UPC2-MS/MS which can be used to identify nineteen and 
quantify fifteen C19 steroids, including all 11OHA4 pathway metabolites, in 5 min 
using a 1.7 μm particle size BEH 2-EP column (Fig. 2). The separation by UPC2 was 
achieved using a flow rate of 2.0 mL.min-1 and ABPR of 2000 PSI. These 
parameters ensured high chromatographic efficiency (supplementary table 1) and 
high throughput, while maintaining an acceptable system backpressure. The 
separation includes four novel steroids which we have identified in the 11OHA4 
pathway, but are not commercially available [15,16]. Although 11KepiAST and 
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11KDHT as well as 3α-adiol and 11OHAST were not resolved these steroids can be 
quantified using their unique MRMs. We found that the separation achieved by UPC2 
was orthogonal to that of reverse-phase LC as the elution order was not simply the 
reverse of that obtained by reverse-phase UPLC, even though normal phase column 
chemistries were employed (Fig. 3). For example the separation of six closely related 
steroids, 11OHA4, 11KA4, 11OHT, 11KT, A4 and T, by conventional reverse-phase 
UPLC resulted in two distinct groupings based on polarity (Fig. 3.a), with A4 and T 
being the least polar. The separation of the same six steroids by UPC2 did not 
demonstrate the same groupings, but instead yielded a mixed elution order (Fig. 
3.b). The altered selectivity achieved by UPC2 is further illustrated in Fig. 4 in which 
the elution order of nineteen C19 steroids separated by reverse-phase UPLC is 
plotted against to the elution order obtained by the UPC2 method. 
3.2 Mass Spectrometry  
The UPC2 eluent was mixed with the makeup ﬂuid to ensure the ionization of the 
steroids by ESI. The ﬂow rate and the composition of makeup ﬂuid were optimized 
with respect to the ionization efficiency of steroids (the makeup fluid is required for 
the ionization). The optimal flow rate was found to be 0.2 mL min-1. Methanol 
containing 1% formic acid provided good ionization efficiency for the steroid 
metabolites. The ionization and fragmentation behaviour of individual steroids 
obtained on the UPC2-MS/MS system is the same as that obtained by UPLC-MS/MS 
(table 1). Apart from a few exceptions, the most abundant ions obtained in positive-
ion mode are protonated species [M + H]+. The most abundant ions obtained for 
AST, epiAST, 11OHAST and 11OHepiAST were [M – H2O + H]
+. 
3.3 Performance and Validation 
13 
 
3.3.1 Calibration range 
Comprehensive method validation was performed for the 15 steroids which are 
available commercially (table 2). LOQs ranged from 0.01 to 10 ng mL-1, 
demonstrating the ionization efficiencies of the different steroids. A 50 fold increase 
in sensitivity for steroids which ionize easily, such as T and A4, was observed when 
comparing a Waters Acquity UPLC coupled to a Xevo TQ mass spectrometer to the 
UPC2 system coupled to the Xevo TQ-S mass spectrometer.  We also observed 
significant improvements in the LOQ’s for difficult to ionize steroids, such as DHT (5 
fold). These improvements were despite a 10-fold lower injection volume. The LOQs 
achieved using the UPC2-Xevo TQ-S system allow for the quantification of steroids 
at levels which were previously not possible. The current method can also be used 
for the detection and relative quantification of the novel steroids 11OH-5α-dione, 
11K-5α-dione, 11OHDHT and 11K-3α-adiol. As these steroids are not commercially 
available they could not be accurately quantified and therefore were excluded from 
comprehensive validation. The calibration range achieved with the Xevo TQ is linear 
up to a concentration of 500 ng mL-1, but only 100 ng mL-1 when using the Xevo TQ-
S, due to the improved sensitivity of the latter system (table 2). Quadratic fits with 
acceptable r2-values (> 0.9906) were obtained for standard curves which included a 
250 ng mL-1 standard, however, due to saturation of the detector precision and 
accuracy were both greater than 20% at this concentration and this standard was 
therefore excluded from the calibration range. The upper limit of quantification 
(ULOQ) was therefore 100 ng mL-1. 
3.3.2 Accuracy and precision 
14 
 
Accuracy and precision were determined at a minimum of three concentrations 
within the calibration range of each steroid and are shown in tables 1 and 2, 
respectively. Acceptable RSDs were obtained for all concentrations for both 
accuracy and precision, which was determined across three days (table 3) [20]. Both 
accuracy and precision were less than 15% at concentrations of 50 and 100 ng mL-1 
(medium and high). Accuracy at low concentrations ranged from 10 to 17% at 0.25 
ng mL-1, 7 to 20% at 2.5 ng mL-1 and 8 to 20% at 25 ng mL-1. Precision at low 
concentrations ranged from 1 to 14% at 0.25 ng mL-1, 4 to 19% at 2.5 ng mL-1 and 2 
to 15% at 25 ng mL-1. Within-laboratory reproducibility is shown in supplementary 
table 2. 
3.3.3 Recovery, matrix effect and process efficiency 
Recovery, matrix effect and process efficiency are shown in table 4. Recovery 
ranged from 54.7 to 78.1% at the low concentration. Recovery values between 74.9 
– 121.1% were obtained at medium and high concentrations (50 and 100 ng mL-1). 
Matrix effects ranged from 18.7% ion suppression for 11KDHT to 20.8% ion 
enhancement for 11KepiAST). The average process efficiency, which is a 
combination of recovery and matrix effect, ranged from 55.4 to 78.5% at a 
concentration of 2.5 ng mL-1 and 73.6 to 114.7% at concentrations of 50 and 100 ng 
mL-1. 
 
4 Discussion 
We have developed a novel UPC2-MS/MS method to study androgen metabolism. 
This method identifies 19 steroids including those in the newly identified 11OHA4 
pathway in a high-throughput method of less than 5 min. Separation by UPC2 was 
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superior to that achieved by reversed phase UPLC based on superior selectivity and 
increased chromatographic efficiency (supplementary table 1). The selectivity 
obtained by UPC2 resulted in a scattered elution order compared to that of the UPLC 
(Fig. 3, Fig. 4) [8,15]. This exceptional selectivity is ideal for the chromatographic 
separation of compounds such as steroids, which have both similar structures and 
mass spectra.  
The sensitivity of the developed method is also superior (5-50 times improvement in 
signal) to any current available methods (without derivatization). The increased 
sensitivity is due to a combination of the optimal flow rate achieved by setting the 
make-up pump [21–23] and the reduction of interfering neutral contaminants by the 
StepWave ion guide [24]. The only drawback to the increased sensitivity is the 
reduced linear range due to saturation of the detector at higher concentrations. This 
is, however, easily overcome by further sample dilution. The increased sensitivity for 
the first time allows us to investigate steroid metabolism in cell culture at 
physiological concentrations. For example we have been able to measure the 
metabolism of 10 nM 11KT and T by prostate cancer cell lines [18]. Such 
experiments have previously relied on the use of supraphysiological substrate 
concentrations due to limitations in sensitivity. Moreover, increased sensitivity is 
achieved using injection volumes of only 2 μL, while conventional UPLC-MS/MS 
methods rely on injection volumes of 5 to 20 μL in order to achieve satisfactory 
sensitivities. The reduced injection volume is a significant advantage when working 
with biological samples in which the amount of sample is limited. Alternatively the 
reduced injection volume allows for multiple injections to be completed from the 
same sample. All other parameters, such as accuracy, precision and matrix effects 
were equivalent to those achieved by UHPLC-MS/MS.     
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5 Conclusion 
The current method has been developed specifically as a tool to study the role of 
androgen metabolism in the development and progression of CRPC, but also serves 
to demonstrate the increased selectivity and sensitivity which can be achieved by 
UPC2-MS/MS over conventional UPLC-MS/MS. The timing of this new technology is 
opportune as there is currently a drive within the field of endocrinology to phase out 
the use of immunoassays in favour of validated MS-based assays [25–27]. This 
method has clearly demonstrated that the selectivity and reduced run times achieved 
by UPC2 are ideal for both clinical and research settings as they allow for the 
simultaneous quantification of numerous steroid metabolites, while at the same time 
achieving high throughput. Supercritical CO2 is also inexpensive when compared to 
organic solvents and has a significantly reduced environmental impact [11]. The 
inclusion of the latest MS technology which incorporates steps to reduce neutral 
contaminants in combination with the UPC2 inlet system results in increases in 
sensitivity which are ideal for the quantification of physiological levels of steroid 
hormones from complex biological matrices.  
The sensitivity and selectivity achieved by this method makes it ideally suited for 
multiple in vitro and in vivo applications, such as investigations into CRPC, testicular, 
breast, ovarian, colon, endometrial, adrenal and other hormone dependent cancers, 
where the role of these novel androgens is unclear. The quantification range is ideal 
for the use in cell culture, xenograft, tissue, serum and plasma samples. While to 
utility of this method for hormone related cancers is apparent, other applications can 
be imagined such as in patients with disorders of sexual differentiation (DSD) where 
altered steroid metabolism is observed. It is possible that there is a previously 
undiscovered role for these androgens in patients with DSD and further research is 
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needed to elucidate this. This method therefore unlocks possibilities for new 
applications which can benefit from the enhanced separation and detection offered 
by UPC2-MS/MS. 
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Figure 1. Schematic representation of the 11OHA4 pathway. 3αHSD, 3α-
hydroxysteroid dehydrogenase; 11βHSD2, 11β-hydroxysteroid dehydrogenase type 
2; 11K-3α-adiol, 11-keto-3α-androstanediol; 11K-5α-dione, 11-keto-5α-
androstanedione; 11KA4, 11-ketoandrostenedione; 11KAST, 11-ketoandrosterone; 
11KDHT, 11-keto-5α-dihydrotestosterone; 11KT, 11-ketotestosterone; 11OH-5α-
dione, 11β-hydroxy-5α-androstanedione; 11OHA4, 11β-hydroxyandrostenedione; 
11OHAST, 11β-hydroxyandrosterone; 11OHT, 11β-hydroxytestosterone; 17βHSD2, 
17β-hydroxysteroid dehydrogenase type 2; AKR1C3, aldo-keto reductase 1C3; 
SRD5A1, steroid 5α-reductase type 1. 
Figure 2. UPC2-MS/MS chromatogram depicting the elution order of C19 steroids. 
The steroids 5α-dione (1), A4 (2), 11K-5α-dione (3), 11KA4 (4), DHT (5), epiAST (6), 
11OH-5α-dione (7), T (8), 11KAST (9), 11OHA4 (10), 11KepiAST (11), 11KDHT 
(12), 3α-adiol (13), 11OHAST (14), 11KT (15), 11OHepiAST (16), 11OHDHT (17), 
11K-3α-adiol (18) and 11OHT (19) were separated by UPC2 (ACQUITY UPC2, 
Waters, Milford, USA) using an ACQUITY UPC2 BEH 2-EP (3.0 mm X 100 mm, 1.7 
μm) column. 
 
Figure 3. Chromatographic separation of 11KA4 (1), 11KT (2), 11OHA4 (3), 11OHT 
(4), A4 (5) and T (6) by (a) UPLC-MS/MS and (b) UPC2-MS/MS.  
 
Figure 4. Graphic depicting the orthogonal elution order of androgens by UPLC and 
UPC2.
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Table 1. Molecular ion species, MRM mass transitions, mass spectrometer parameters 
(cone voltage, collision energy) and retention time for each steroid. Internal standard: 
PROG-d9, 17OHPROG-d9, T-d2, Cortisol-d4, DRSP and GES. 
 
 
Mass transitions    
Abbreviation 
 
Name Quantifier Qualifier 
Cone 
Voltage 
(V) 
Collision 
Energy 
(eV) 
Retention  
Time  
(min) 
11OHA4 11β-hydroxyandrostenedione 303.2>267.2 303.2>121.0 30 30 30 15 2.20 
11KA4 11-ketoandrostenedione 301.2>257.0 301.2>265.2 35 35 25 25 1.30 
11OHT 11β-hydroxytestosterone 305.3>121.0 305.3>269.0 35 35 20 15 3.79 
11KT 11-ketotestosterone 303.2>121.0 303.2>267.0 30 30 20 20 2.70 
11OH-5α-
dione 
11β-hydroxy 5α-
androstanedione 
305.0>269.2 305.0>287.2 35 35 15 15 1.52 
11K-5α-dione 11-keto-5α-androstanedione 303.2>241.0 303.2>267.0 35 35 30 25 0.90 
11OHDHT 
11β-hydroxy-5α-
dihydrotestosterone 
307.0>253.0 307.0>271.0 35 35 20 20 3.12 
11KDHT 11-ketodihydrotestosterone 305.2>243.0 305.2>269.0 30 30 20 20 2.46 
11OHAST 11β-hydroxyandrosterone 289.0>271.0 289.0>213.0 15 15 15 15 2.62 
11OHepiAST 11β-hydroxyepiandrosterone 289.0>271.0 289.0>213.0 15 15 15 15 2.88 
11KAST 11-ketoandrosterone 305.0>147.2 305.0>173.1 30 30 30 30 2.04 
11KepiAST 11-ketoepiandrosterone 305.0>147.2 305.0>173.1 30 30 30 30 2.46 
11K-3α-adiol 
11-keto 5α-androstane-3α,17β-
diol 
307.2>271.0 307.2>253.0 15 15 10 10 3.56 
A4 Androstenedione 287.2>96.9 287.2>108.8 30 30 15 15 0.88 
Testosterone Testosterone 289.2>97.2 289.2>109.0 30 30 22 22 1.86 
5α-dione 5α-androstanedione 289.2>253.1 289.2>97.2 22 30 16 22 0.57 
DHT 5α-dihydrotestosterone 291.2>255.0 291.2>273.0 25 25 15 20 1.38 
epiAST Epiandrosterone 273.2>105.4 291.3>273.4 30 18 30 8 1.45 
3α-adiol 5α-androstane-3α,17β-diol 275.2>257.0 275.2>175.0 15 15 15 15 2.62 
         
PROG-d9 
Progesterone-2, 2, 4, 6, 6, 17α, 
21, 21, 21-d9 
324.2>100.0 324.2>113.0 30 30 20 25 0.84 
17OHPROG-
d9 
4-Pregnen-17α-ol-3,20-dione-2, 
2, 4, 6, 6, 21, 21, 21-d8 
340.1>100.0 340.1>114.0 26 26 25 28 1.75 
T-d2 Testosterone-1, 2-d2 291.0>99.1 291.0>111.2 30 30 20 30 1.86 
Cortisol-d4 Cortisol-9, 11, 12, 12-d4 367.0>121.0  35  25  4.24 
DRSP Drospirenone 367.2>97.3 367.2>159.3 20 20 30 25 2.24 
GES Gestodene 311.2>109.4 311.2>135.0 15 15 25 25 1.62 
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Table 2. Comprehensive method validation data: LOD (ng mL-1); LOQ (ng mL-1); Range (ng mL-1); r2; Accuracy (RSD %, n= 8). 
Steroids 
LOD LOQ  Range  
r2 
Accuracy RSD % 
(ng mL-1) 
(pg on column) 
(ng mL-1) 
(pg on column) 
(ng mL-1) (ng mL-1) 
          0,25 2,5 25 50 100 
11OHA4 0.01 (0.13) 0.01 (0.13) 0.01 - 100 0.9917 16.0% 7.0% 11.5% 5.1% 2.6% 
11KA4 0.01 0.13) 0.01 (0.13) 0.01 - 50 0.9977 17.5% 13.3% 12.0% 13.9% 9.1% 
11OHT 0.01 (0.13) 0.01 (0.13) 0.01 - 100 0.9946 14.0% 10.0% 8.4% 9.3% 6.0% 
11KT 0.01 (0.13) 0.01 (0.13) 0.01 - 100 0.9989 13.1% 14.6% 8.6% 5.3% 5.9% 
11KDHT 0.25 (3.33) 1 13.3) 0.25 - 100 0.9996 <LOQ 15.0% 9.2% 7.1% 6.0% 
11OHAST 5 (66.7) 10 (133.3) 10 - 100 0.9985 <LOQ <LOQ 11.7% 9.4% 13.0% 
11OHepiAST 5 (66.7) 10 (133.3) 10 - 100 0.986 <LOQ <LOQ 20.3% 9.5% 12.0% 
11KAST 5 (66.7) 5 66.7) 5 - 100 0.9958 <LOQ <LOQ 11.4% 6.5% 8.4% 
11KepiAST 10 (133.3) 10 (133.3) 10 - 100 0.9951 <LOQ <LOQ 18.5% 7.6% 8.0% 
A4 <0.01 (<0.13) 0.01 (0.13) 0.01 - 100 0.9851 13.4% 9.3% 7.5% 5.4% 9.0% 
T <0.01 (<0.13) 0.01 (0.13) 0.01 - 50 0.992 10.0% 20.1% 8.4% 4.0% 4.9% 
5α-dione 0.25 (3.33) 0.5 (6.67) 0.5 - 100 0.9941 <LOQ 16.5% 18.5% 9.7% 7.7% 
DHT 0.25 (3.33) 1 (13.3) 1 - 100 0.9942 <LOQ 13.0% 12.4% 11.3% 9.7% 
epiAST 0.25 (3.33) 1 (13.3) 1 - 100 0.9952 <LOQ 15.1% 9.9% 6.0% 10.0% 
3α-adiol 1 (13.3) 5 (66.7) 5 - 100 0.9977 <LOQ <LOQ 13.5% 7.2% 11.5% 
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Table 3. Comprehensive method validation data continued: Precision with interday variation (RSD %, n= 6). 
Steroids 
  Precision RSD %   
 
Day 1 
 
Day 2 
 
Day 3   
                  
 
 
Concentration   
 
(ng mL-1)   
  0.25 2.5 25 50 100 
 
0.25 2.5 25 50 100 
 
0.25 2.5 25 50 100   
11OHA4 
 
9.8% 3.9% 8.1% 3.6% 2.8% 
 
7.6% 19.1% 7.5% 6.5% 8.4% 
 
14.2% 12.6% 8.5% 5.0% 2.9%   
11KA4 
 
11.8% 11.7% 15.1% 1.9% 2.9% 
 
9.8% 11.7% 2.0% 3.9% 5.0% 
 
8.8% 12.5% 3.8% 4.9% 3.5%   
11OHT 
 
2.6% 15.2% 4.5% 5.4% 10.2% 
 
9.5% 11.8% 8.1% 5.7% 7.4% 
 
12.5% 11.4% 7.0% 6.7% 3.8%   
11KT 
 
4.4% 8.3% 6.5% 4.0% 3.7% 
 
8.7% 7.0% 9.5% 6.5% 7.2% 
 
10.9% 12.8% 6.6% 6.0% 5.6%   
11KDHT 
 
<LOQ 13.5% 8.4% 3.4% 3.7% 
 
<LOQ 11.8% 8.0% 5.4% 9.1% 
 
<LOQ 4.7% 5.3% 7.9% 13.3%   
11OHAST 
 
<LOQ <LOQ 8.2% 5.0% 6.7% 
 
<LOQ <LOQ 10.2% 4.9% 6.1% 
 
<LOQ <LOQ 11.3% 5.7% 3.6%   
11OHepiAST 
 
<LOQ <LOQ 11.3% 5.1% 2.7% 
 
<LOQ <LOQ 5.5% 2.8% 8.7% 
 
<LOQ <LOQ 5.6% 4.2% 5.1%   
11KAST 
 
<LOQ <LOQ 10.4% 3.5% 3.5% 
 
<LOQ <LOQ 4.6% 3.6% 6.1% 
 
<LOQ <LOQ 6.8% 3.4% 4.0%   
11KepiAST 
 
<LOQ <LOQ 13.6% 5.8% 2.9% 
 
<LOQ <LOQ 8.5% 7.9% 6.4% 
 
<LOQ <LOQ 14.2% 12.5% 9.5%   
A4 
 
5.2% 9.7% 5.4% 2.6% 4.4% 
 
4.2% 11.3% 2.9% 3.3% 4.0% 
 
4.3% 8.0% 4.2% 4.1% 4.2%   
T 
 
3.2% 9.5% 6.5% 2.4% 2.4% 
 
1.2% 11.2% 2.1% 4.7% 2.9% 
 
5.0% 11.0% 3.9% 4.4% 4.2%   
5α-dione 
 
<LOQ 9.8% 6.2% 2.6% 5.6% 
 
<LOQ 15.0% 9.2% 8.1% 5.8% 
 
<LOQ 15.5% 6.3% 5.0% 4.8%   
DHT 
 
<LOQ 10.5% 8.8% 2.9% 2.2% 
 
<LOQ 9.6% 6.4% 6.2% 5.9% 
 
<LOQ 9.8% 3.2% 5.7% 6.2%   
epiAST 
 
<LOQ 14.7% 12.3% 7.6% 3.9% 
 
<LOQ 15.5% 10.8% 8.9% 6.5% 
 
<LOQ 9.5% 5.6% 4.6% 8.5%   
3α-adiol   <LOQ <LOQ 9.2% 11.6% 2.3% 
 
<LOQ <LOQ 5.4% 6.6% 6.5% 
 
<LOQ <LOQ 9.9% 6.7% 9.8%   
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Table 4. Comprehensive method validation data continued, Recovery (%, n=3); Matrix Effect 
(%, n=3) and Process Efficiency (%, n=3). 
Steroids 
Recovery % 
ng mL-1 
Matrix effect % 
ng mL-1 
Process Efficiency % 
ng mL-1 
  2,5 50 100 2,5 50 100 2,5 50 100 
11OHA4 63.1 109.0 106.0 8.9 -8.0 -12.4 68.7 100.2 92.8 
11KA4 77.8 101.0 105.5 -19.0 -1.0 -16.9 63.0 100.0 87.6 
11OHT 64.7 109.1 109.6 13.3 5.2 -10.6 73.4 114.7 98.0 
11KT 56.4 83.6 80.4 1.9 1.7 6.8 57.4 85.1 85.9 
11KDHT 78.1 121.1 108.6 -14.2 -16.6 -18.7 67.0 101.0 88.3 
11OHAST <LOQ 85.8 88.7 35.3 -0.8 -3.5 65.0 85.1 85.6 
11OHepiAST <LOQ 96.0 88.0 40.1 17.7 13.8 97.5 113.1 100.1 
11KAST <LOQ 106.8 94.2 3.7 -6.2 -2.2 86.8 100.2 92.1 
11KepiAST <LOQ 78.1 87.1 7.5 20.8 0.6 73.2 94.4 87.6 
A4 62.9 89.6 74.9 2.8 -3.2 -1.7 64.7 86.7 73.6 
T 62.0 103.0 90.8 11.0 -1.8 1.1 68.8 101.1 91.9 
5α-dione 55.7 112.4 85.6 -0.4 -15.6 -4.2 55.4 94.9 82.0 
DHT 64.0 102.2 112.6 -5.9 -9.1 -17.1 60.2 92.9 93.4 
epiAST 72.5 102.0 114.8 8.4 -1.0 -13.3 78.5 100.9 99.5 
3α-adiol 54.7 92.3 119.0 28.4 11.3 -12.8 70.2 102.6 103.8 
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